When the Intestine Can’t Keep Up, Everything Suffers.
Short Bowel Syndrome (SBS) is more than a digestive issue—it’s a lifelong battle against malnutrition, fatigue, and limited options. Eclipse Regenesis is working to change that.
What is Short Bowel Syndrome (SBS)?
Short Bowel Syndrome (SBS) occurs when a significant portion of the small intestine is missing or nonfunctional, usually due to surgical removal, birth defects, or disease. Without enough intestinal surface area, the body cannot absorb the nutrients and fluids it needs to survive.
SBS affects approximately 10,000-20,000 people in the U.S. alone. While it’s considered rare, for those living with it, the impact is constant and severe.
What Causes Short Bowel Syndrome (SBS)?
Short Bowel Syndrome (SBS) is typically the result thereof the surgical removal of intestine. There are many reasons a patient has undergone intestinal resection (removal). These reasons in pediatric patients may be one of the following:
- Necrotizing Enterocolitis (NEC), is the most common cause of intestinal resection. Necrotizing Enterocolitis (NEC) takes place when the lining of the intestinal wall becomes infected and therefore dies.
- Birth Defects such as: Gastroschisis, Volvulus, Hirschsprung’s Disease, Intestinal Atresia, and other congenital defects.
Current Treatment Limitations
Treatment Hasn’t Changed in Decades.
Most treatment options for SBS are supportive—not restorative. They help patients manage symptoms, but they don’t address the core issue: the lack of functioning intestine.
Current options include:
Total Parenteral Nutrition (TPN)
- Lifelong Intravenous (IV) feeding and nutritional support
- Frequent hospitalizations for venous catheter-associated complications (infections, displacement, etc.)
- Toxicity often leading to end-stage liver disease
Drug Therapy (Teduglutide Injections)
- Daily injections
- Minimal improvement in absorption (max 20%)
- TPN/IV nutrition still required
Surgery and Intestinal Transplantation
- May not increase nutrient absorption
- May require lifelong immunosuppression drugs
- High risk of infection, rejection, death
What is The Impact of Short Bowel Syndrome (SBS)?
An unfortunately growing impact that we are committed to change.
Patients suffer from malabsorption and malnutrition.
40% of neonatal patients die before age 3.
$1.6M patient cost over 5 years.
$3B+/year total cost to healthcare system.
A Regenerative Future.
We see a different future, one where the body can regrow what was lost. Our technology is designed to stimulate natural intestinal regeneration, offering hope for patients once told there was none.
You’re Not Alone.
Whether you’re a parent, a patient, or a provider, we’re here to support your journey. Learn more about our clinical trial, connect with our team, or join our updates list to follow our progress.